View Financial HealthSpineway 配当と自社株買い配当金 基準チェック /06Spineway配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 01Spineway SA to Report First Half, 2026 Results on Jul 30, 2026Spineway SA announced that they will report first half, 2026 results on Jul 30, 2026お知らせ • Mar 09Spineway SA, Annual General Meeting, Apr 02, 2026Spineway SA, Annual General Meeting, Apr 02, 2026. Location: 7 allee du moulin berger, batiment 7, ecully Franceお知らせ • Jan 14Spineway SA to Report Fiscal Year 2025 Results on Feb 17, 2026Spineway SA announced that they will report fiscal year 2025 results on Feb 17, 2026Board Change • Dec 30Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 02Spineway SA, Annual General Meeting, Jun 04, 2025Spineway SA, Annual General Meeting, Jun 04, 2025. Location: 7 allee du moulin berger, batiment 7, ecully Franceお知らせ • Jan 23Spineway SA to Report Fiscal Year 2024 Results on Mar 24, 2025Spineway SA announced that they will report fiscal year 2024 results on Mar 24, 2025New Risk • Oct 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Market cap is less than US$10m (€132.6k market cap, or US$143.1k). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€300k net loss in 2 years).お知らせ • Jul 25Spineway SA to Report First Half, 2024 Results on Sep 24, 2024Spineway SA announced that they will report first half, 2024 results on Sep 24, 2024お知らせ • Feb 09Spineway SA, Annual General Meeting, Mar 25, 2024Spineway SA, Annual General Meeting, Mar 25, 2024.Reported Earnings • Feb 09Full year 2023 earnings releasedFull year 2023 results: Revenue: €10.5m (up 23% from FY 2022). Net loss: €6.51m (loss widened 108% from FY 2022).お知らせ • Jan 26Spineway SA to Report Q4, 2023 Results on Feb 07, 2024Spineway SA announced that they will report Q4, 2023 results on Feb 07, 2024お知らせ • Nov 08Spineway Sa Announces the Appointment of Sandrine Carle as Deputy Chief Executive OfficerThe Spineway Group announced the appointment of Sandrine Carle as Deputy Chief Executive Officer. Ms. Carle joined Spineway in July 2022, at the time of the acquisition of Spine Innovations, where she was CEO. She was instrumental in the successful integration of Spine Innovations into the Spineway Group. After earning a degree as a biomedical engineer (UT Compiègne) and an Executive MBA at HEC in Paris, Sandrine Carle worked for over 20 years in the orthopedic surgery sector, and more specifically in the spinal surgery sector at Medtronic (Europe), Kyphon (USA) and Vexim (France). She held marketing and management positions in France and the USA before being appointed CEO of Spine Innovations in 2020. Ms. Carle led the creation of this entity following a spin-off in 2020 and the development of this activity between 2020 and 2022. She led the recruitment and management of around fifteen employees, set up the functional and operational organization of the team and also obtained the company’s certification from the notified body, G-MED (France). Working alongside Stéphane Le Roux, CEO of Spineway, Sandrine Carle is responsible for conducting the Group’s overall roadmap, in particular the business development plan aimed at returning to operating breakeven, as well as all R&D projects (short, medium and long term).お知らせ • Oct 20Spineway Group Obtains 510(K) Clearance from the US Food and Drug Administration for its VEOS Spinal Fixation SystemSpineway Group announced the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System. This clearance, which allows Spineway Group to market its VEOS system in the US, represents a significant achievement for the Group and reinforces its strategic approach to develop its business in the US market. This recognition also demonstrates the Group's commitment to provide innovative solutions to surgeons and to put the well-being of patients first. This innovative medical device is presented at the North American Spine Society (NASS) Congress in Los Angeles until 21 October 2023. The VEOS Spinal Fixations System is a complete platform that offers an innovative and versatile solution tailored to surgeons' needs. The VEOS platform is easy to use, fully modular and optimizes operational excellence in operating room. This new offering enables surgeons to perform open, minimally invasive and percutaneous surgery (MIS) for the treatment of a wide range of spinal pathologies, from degenerative spine to complex surgery and deformities.Reported Earnings • Sep 21First half 2023 earnings releasedFirst half 2023 results: Revenue: €5.43m (up 51% from 1H 2022). Net loss: €1.89m (loss widened 136% from 1H 2022).New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 0.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€575.5k market cap, or US$625.1k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Jul 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 8x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€987.0k market cap, or US$1.09m).Breakeven Date Change • Apr 09Forecast to breakeven in 2023The analyst covering Spineway expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Earnings growth of 139% is required to achieve expected profit on schedule.Reported Earnings • Feb 14Full year 2022 earnings releasedFull year 2022 results: Revenue: €7.43m (up 48% from FY 2021). Net loss: €3.14m (loss widened 98% from FY 2021). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.お知らせ • Feb 02Spineway SA to Report First Half, 2023 Results on Sep 19, 2023Spineway SA announced that they will report first half, 2023 results on Sep 19, 2023お知らせ • Jan 25Spineway SA to Report Fiscal Year 2022 Results on Feb 09, 2023Spineway SA announced that they will report fiscal year 2022 results After-Market on Feb 09, 2023Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 10First half 2022 earnings releasedFirst half 2022 results: Revenue: €3.11m (up 27% from 1H 2021). Net loss: €803.0k (loss widened 30% from 1H 2021).Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 04Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: €0 (up from €0.005 loss in FY 2020). Revenue: €5.04m (up 12% from FY 2020). Net loss: €1.58m (loss narrowed 89% from FY 2020). Revenue missed analyst estimates by 39%. Earnings per share (EPS) were in line with analyst estimates.Breakeven Date Change • Jul 27Forecast to breakeven in 2023The analyst covering Spineway Société Anonyme expects the company to break even for the first time. New forecast suggests the company will make a profit of €2.10m in 2023. Average annual earnings growth of 88% is required to achieve expected profit on schedule.決済の安定と成長配当データの取得安定した配当: 37Sの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 37Sの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Spineway 配当利回り対市場37S 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (37S)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.7%業界平均 (Medical Equipment)2.8%アナリスト予想 (37S) (最長3年)0%注目すべき配当: 37Sは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 37Sは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 37Sの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 37Sが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 21:00終値2026/06/11 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Spineway SA 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Mohamed KaabouniPortzamparc BNP Paribas
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 01Spineway SA to Report First Half, 2026 Results on Jul 30, 2026Spineway SA announced that they will report first half, 2026 results on Jul 30, 2026
お知らせ • Mar 09Spineway SA, Annual General Meeting, Apr 02, 2026Spineway SA, Annual General Meeting, Apr 02, 2026. Location: 7 allee du moulin berger, batiment 7, ecully France
お知らせ • Jan 14Spineway SA to Report Fiscal Year 2025 Results on Feb 17, 2026Spineway SA announced that they will report fiscal year 2025 results on Feb 17, 2026
Board Change • Dec 30Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 02Spineway SA, Annual General Meeting, Jun 04, 2025Spineway SA, Annual General Meeting, Jun 04, 2025. Location: 7 allee du moulin berger, batiment 7, ecully France
お知らせ • Jan 23Spineway SA to Report Fiscal Year 2024 Results on Mar 24, 2025Spineway SA announced that they will report fiscal year 2024 results on Mar 24, 2025
New Risk • Oct 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Market cap is less than US$10m (€132.6k market cap, or US$143.1k). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€300k net loss in 2 years).
お知らせ • Jul 25Spineway SA to Report First Half, 2024 Results on Sep 24, 2024Spineway SA announced that they will report first half, 2024 results on Sep 24, 2024
お知らせ • Feb 09Spineway SA, Annual General Meeting, Mar 25, 2024Spineway SA, Annual General Meeting, Mar 25, 2024.
Reported Earnings • Feb 09Full year 2023 earnings releasedFull year 2023 results: Revenue: €10.5m (up 23% from FY 2022). Net loss: €6.51m (loss widened 108% from FY 2022).
お知らせ • Jan 26Spineway SA to Report Q4, 2023 Results on Feb 07, 2024Spineway SA announced that they will report Q4, 2023 results on Feb 07, 2024
お知らせ • Nov 08Spineway Sa Announces the Appointment of Sandrine Carle as Deputy Chief Executive OfficerThe Spineway Group announced the appointment of Sandrine Carle as Deputy Chief Executive Officer. Ms. Carle joined Spineway in July 2022, at the time of the acquisition of Spine Innovations, where she was CEO. She was instrumental in the successful integration of Spine Innovations into the Spineway Group. After earning a degree as a biomedical engineer (UT Compiègne) and an Executive MBA at HEC in Paris, Sandrine Carle worked for over 20 years in the orthopedic surgery sector, and more specifically in the spinal surgery sector at Medtronic (Europe), Kyphon (USA) and Vexim (France). She held marketing and management positions in France and the USA before being appointed CEO of Spine Innovations in 2020. Ms. Carle led the creation of this entity following a spin-off in 2020 and the development of this activity between 2020 and 2022. She led the recruitment and management of around fifteen employees, set up the functional and operational organization of the team and also obtained the company’s certification from the notified body, G-MED (France). Working alongside Stéphane Le Roux, CEO of Spineway, Sandrine Carle is responsible for conducting the Group’s overall roadmap, in particular the business development plan aimed at returning to operating breakeven, as well as all R&D projects (short, medium and long term).
お知らせ • Oct 20Spineway Group Obtains 510(K) Clearance from the US Food and Drug Administration for its VEOS Spinal Fixation SystemSpineway Group announced the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System. This clearance, which allows Spineway Group to market its VEOS system in the US, represents a significant achievement for the Group and reinforces its strategic approach to develop its business in the US market. This recognition also demonstrates the Group's commitment to provide innovative solutions to surgeons and to put the well-being of patients first. This innovative medical device is presented at the North American Spine Society (NASS) Congress in Los Angeles until 21 October 2023. The VEOS Spinal Fixations System is a complete platform that offers an innovative and versatile solution tailored to surgeons' needs. The VEOS platform is easy to use, fully modular and optimizes operational excellence in operating room. This new offering enables surgeons to perform open, minimally invasive and percutaneous surgery (MIS) for the treatment of a wide range of spinal pathologies, from degenerative spine to complex surgery and deformities.
Reported Earnings • Sep 21First half 2023 earnings releasedFirst half 2023 results: Revenue: €5.43m (up 51% from 1H 2022). Net loss: €1.89m (loss widened 136% from 1H 2022).
New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 0.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€575.5k market cap, or US$625.1k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Jul 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 8x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€987.0k market cap, or US$1.09m).
Breakeven Date Change • Apr 09Forecast to breakeven in 2023The analyst covering Spineway expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Earnings growth of 139% is required to achieve expected profit on schedule.
Reported Earnings • Feb 14Full year 2022 earnings releasedFull year 2022 results: Revenue: €7.43m (up 48% from FY 2021). Net loss: €3.14m (loss widened 98% from FY 2021). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Feb 02Spineway SA to Report First Half, 2023 Results on Sep 19, 2023Spineway SA announced that they will report first half, 2023 results on Sep 19, 2023
お知らせ • Jan 25Spineway SA to Report Fiscal Year 2022 Results on Feb 09, 2023Spineway SA announced that they will report fiscal year 2022 results After-Market on Feb 09, 2023
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 10First half 2022 earnings releasedFirst half 2022 results: Revenue: €3.11m (up 27% from 1H 2021). Net loss: €803.0k (loss widened 30% from 1H 2021).
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 04Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: €0 (up from €0.005 loss in FY 2020). Revenue: €5.04m (up 12% from FY 2020). Net loss: €1.58m (loss narrowed 89% from FY 2020). Revenue missed analyst estimates by 39%. Earnings per share (EPS) were in line with analyst estimates.
Breakeven Date Change • Jul 27Forecast to breakeven in 2023The analyst covering Spineway Société Anonyme expects the company to break even for the first time. New forecast suggests the company will make a profit of €2.10m in 2023. Average annual earnings growth of 88% is required to achieve expected profit on schedule.